Ideogen
Manufacturing · Switzerland · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Hurdnerstrasse 119, Hurden, Schwyz, 8640...Phone Number
+41 433115252Website
www.ideogen.comRevenue
$8.9 MillionIndustry
About Ideogen
Ideogen Org Chart
Is Ideogen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Ideogen
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Ideogen, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Ideogen has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Ideogen has new funding data
Earning: See what the market has to say on Ideogen recently announced quarterly report
Click to see if Ideogen had a recent Job posting/layoffs
Product Launch: Get notified when Ideogen launches new products
Check out if Ideogen is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Ideogen as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Ideogen is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ideogen is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ideogen.
Ideogen Tech Stack
A closer look at the technologies used by Ideogen
Ideogen News & Media
Swiss Pharma Company - IDEOGEN takes over Special Access Program for BELEODAQ® (belinostat)
HURDEN, Switzerland, Jan. 21, 2022 /PRNewswire/ -- IDEOGEN GROUP, Managed Access division, takes over Special Access Program for BELEODAQ® (belinostat) in Europe, Middle East, North Africa, Russia, and CIS. BELEODAQ® is a prescription medicine used to treat patients with a rare form of...Emmaus Life Sciences Announces Submission of Marketing Authorization Application to Swissmedic Ideogen, A.G. to Manage Early Access Program
TORRANCE, Calif., June 15, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today it has received confirmation from the Swiss Agency for Therapeutic Products (Swissmedic)...
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ideogen
Ideogen A.G. is a Swiss pharmaceutical group with a primary focus on specialty medicines for unmet medical needs. Ideogen strives to improve patients' quality of life and physicians' access to therapeutic options via managed access programs and approved marketing authorizations in the European continent.... Read More